CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer

Hilbe, Wolfgang

doi:10.1136/jcp.2004.016444

Cited by 184 publications

(151 citation statements)

References 29 publications

Supporting

Mentioning

143

Contrasting

Order By: Relevance

“…+ cells and A549 cells may be due to unique characteristic of CD133 + cells [22][23][24]. It need to be noticed that Meng et al studied the CD133 + and CD133 -A549 cells and found that they exhibited similar abilities of colony formation, invasion [16].…”

Section: Discussionmentioning

confidence: 99%

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Zhang¹,

Yang²,

Sun³

et al. 2014

neo

View full text Add to dashboard Cite

Lung cancer remains a major cause of cancer-related lethality because of high incidence and recurrence in spite of significant advances in staging and therapy. In present study, we identified a subpopulation of cells isolated from the A549 cell line with marker CD133. In vivo results showed that A549 CD133 + cells displayed high liver metastatic potential. Severe liver cell damage with tumor cell invasion revealed by pathological examination and these changes were consistent with the results of serological tests where the plasma GPT and GOT level are significantly higher than that of the control group. Compared with A549 cells, A549 CD133 + cells expressed high levels of VEGF and exhibited high migration and invasion capability. In conclusion, we first reported that A549 CD133 + cells exhibited characteristic of high liver metastatic potential which makes it be a suitable model for further study of liver metastasis of lung adenocarcinoma and provide a potential platform for antimetastatic drug discovery or evaluation. Key words: human lung adenocarcinoma, liver metastasis, migration, invasion, CD133Lung cancer is one of the most aggressive neoplasms in the world [1]. Despite management and treatment of lung cancer has been improved these years, but the prognosis remains poor, the 5-year survival rate of non-small cell lung cancer (NSCLC) is no more than 15 % [2]. Approximately 50 % of NSCLC patients with stage I and II will die from recurrent disease despite conventional therapy, and nearly 70% of lung cancer patients will die from metastatic disease, even after surgical resection of the primary tumor, radiation therapy, and chemotherapy [3]. Thus, it is important to find novel effective therapies to inhibit lung cancer metastasis.The most common four metastatic sites of patients with solitary metastatic NSCLC were: bone, liver, kidney and spleen [3]. Nevertheless, the mechanism of which lung adenocarcinoma selectively disseminated to certain organs remains unknown. However, experimental reproducible animal models facilitate to understand the process of metastasis and can provide suitable models for basic or preclinical studies.Different kinds of cancer metastasis model have been published yet. Early in 1996, Iguchi H et al [4] have established lung cancer metastasis model with human lung squamous cell carcinoma-derived cells (HARA). In 1959, Leduc [5] was the first to describe liver metastasis in mice after injection of hepatoma carcinoma cells in the spleen. Moreover, the liver metastasis models in nude mice of colon carcinoma have been successfully established [6,7]. Early studies in immunodeficient mice illustrated that subcutaneous injection of tumor cells seldom give rise to liver metastases [8].However, no lung adenocarcinoma liver metastasis model has been published so far. CD133 as a marker of cancer stem cells (CSCs) has been demonstrated in many cancers including lung cancer [9][10][11][12][13]. The CSCs theory indicated that subpopulation of tumor cells with stem or progenitor cell characteristics c...

show abstract

Section: Discussionmentioning

confidence: 99%

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Zhang¹,

Yang²,

Sun³

et al. 2014

neo

View full text Add to dashboard Cite

show abstract

“…Although it was initially Da Cruz Paula et al: Phenotypic Heterogeneity of Breast Cancer Stem Cells (Review) considered to be a marker of hematopoietic stem cells, CD133 mRNA transcript is also found in normal nonlymphoid hematopoietic tissue (60) and has been shown to play a role in SC migration and asymmetric division (61). CD133 was reported to be overexpressed in several solid tumors (62,63), including colon cancer and glioblastoma (64,65). In IBCs, CD133 expression was demonstrated by Liu et al (66), where they assumed that its expression could be of help in a more accurate prediction of breast cancer aggressiveness and determination of the most suitable treatment.…”

Section: Cd133 (Prominin-1)mentioning

confidence: 99%

Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer

Paula

Lopes

2017

View full text Add to dashboard Cite

show abstract

“…7,8 These endothelial cells have defining markers such as CD133 and have recently been shown in the vessels of human lung tumors and vessels of tumors in human transplant recipients. 9,10 The majority of work in this area relates to animal models, where inhibition of this cell population has been shown to inhibit tumor growth. In addition, because the endothelial progenitor cells target vasculature, they have been investigated as cellular vectors for delivery of gene therapy.…”

Section: Distinguishing Features Of Tumour Endotheliummentioning

confidence: 99%

Gene therapy targeting to tumor endothelium

2006

View full text Add to dashboard Cite

Tumor-associated vasculature is a relatively accessible component of solid cancers that is essential for tumor survival and growth, providing a vulnerable target for cancer gene therapy administered by intravenous injection. Several features of tumor-associated vasculature are different from normal vasculature, including overexpression of receptors for angiogenic growth factors, markers of vasculogenesis, upregulation of coagulation cascades, aberrant expression of adhesion molecules and molecular consequences of hypoxia. Many of these differences provide candidate targets for tumor-selective 'transductional targeting' of genetically-or chemically modified vectors and upregulated gene expression can also enable 'transcriptional targeting', regulating tumor endothelia-selective expression of transgenes following nonspecific gene delivery. Tumor vasculature also represents an important site of therapeutic action by the secreted products of antiangiogenic gene therapies that are expressed in non-endothelial cells. In this review we assess the challenges faced and the vectors that may be suitable for gene delivery to exploit these targets. We also overview some of the strategies that have been developed to date and highlight the most promising areas of research.

show abstract

CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer

Cited by 184 publications

References 29 publications

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer

Gene therapy targeting to tumor endothelium

Contact Info

Product

Resources

About